Immune Status Influences Proteins on Malaria Parasites

Jim Crocker
29th April, 2025

Immune Status Influences Proteins on Malaria Parasites

A novel monoclonal antibody targeting PfMSP3 effectively blocks the recruitment of complement inhibitor C1-INH to the Plasmodium falciparum merozoite surface (a, b), a function not achieved by naturally acquired antibodies, with cryo-electron microscopy revealing the structural basis for this interaction (c–e).

Image adapted from: Bassi et al. / CC BY (Source)

Key Findings

  • In Ghana, researchers discovered that children’s antibodies fight malaria parasites more effectively than adults’
  • Children’s antibodies better activate the immune system to destroy the parasite by blocking its defense tactics
  • Scientists developed a new antibody that can enhance malaria vaccines by preventing the parasite from evading the immune response
Malaria, caused predominantly by the parasite Plasmodium falciparum, remains a major global health challenge, particularly in sub-Saharan Africa. Understanding how the human immune system combats this parasite is crucial for developing effective vaccines and treatments. Recent research conducted by the University of Copenhagen[1] sheds new light on the mechanisms of naturally acquired immunity and offers promising strategies to enhance vaccine efficacy. In regions where malaria is endemic, individuals gradually develop immunity after multiple exposures to the parasite. This natural immunity is believed to rely heavily on antibodies, which are proteins produced by the immune system to identify and neutralize pathogens. According to a comprehensive review by the University of Ghana[2], naturally acquired immunity can be nearly 100% effective in protecting heavily exposed adults from severe disease and death. This highlights the potential of harnessing and replicating such immune responses in vulnerable populations, especially young children. The study by the University of Copenhagen focused on how these antibodies activate the complement system, a part of the immune system that enhances the ability to clear pathogens. The researchers examined plasma samples from both children and adults in regions of Ghana with high malaria exposure. They discovered that while both groups produced antibodies capable of initiating the complement cascade—beginning with the fixation of C1q—the downstream activation resulting in the formation of the membrane attack complex (MAC) was significantly higher in children. This suggests that the antibodies in children are more effective at leading the complement system to target and destroy the parasite. One of the critical challenges in malaria infection is the parasite's ability to evade the immune system. Plasmodium falciparum has developed strategies to recruit proteins like Factor H (FH) and C1 esterase inhibitor (C1-INH), which down-regulate the complement system and prevent the immune response from eliminating the parasite. The University of Copenhagen’s study revealed that the antibodies from naturally exposed children could interfere with the parasite's recruitment of FH but were ineffective against C1-INH. This partial interference indicates that while the immune response is robust, the parasite still possesses mechanisms to evade complete destruction. Building on these findings, the researchers developed a murine monoclonal antibody targeting PfMSP3, a parasite protein that interacts with C1-INH on the merozoite surface. Merozoites are the forms of the parasite that invade red blood cells, leading to malaria symptoms. By blocking the interaction between PfMSP3 and C1-INH, the monoclonal antibody effectively prevents the parasite from evading the complement system. Structural analysis using cryogenic electron microscopy provided the first detailed look at how this antibody binds to PfMSP3, offering valuable insights for vaccine design. This approach aligns with previous research on malaria vaccines targeting specific parasite proteins. For instance, studies on PfCyRPA[3] and PfRipr[4] have identified these proteins as key targets for inducing protective antibodies that prevent erythrocyte invasion. Additionally, research on other vaccine candidates like AMA1 and MSP1(42)[5] has demonstrated varying levels of effectiveness in inhibiting parasite growth. By combining these approaches, the new strategy proposed by the University of Copenhagen aims to enhance vaccine efficacy by simultaneously targeting multiple mechanisms the parasite uses to survive. The integration of these findings suggests a multifaceted approach to malaria vaccination. By directing the immune response toward both the leading vaccine candidates and the parasite's complement evasion strategies, it may be possible to achieve more comprehensive protection. This could lead to vaccines that not only prevent severe disease and death but also reduce the overall transmission of the parasite. In conclusion, the University of Copenhagen’s study provides significant advancements in our understanding of naturally acquired immunity to malaria. By uncovering how antibodies from exposed individuals activate the complement system and identifying new targets to prevent parasite evasion, this research paves the way for the development of more effective malaria vaccines. Combining these insights with existing knowledge on other vaccine targets could ultimately lead to breakthroughs in the fight against this devastating disease.

MedicineHealthBiochem

References

Main Study

1) Deposition of complement regulators on the surface of Plasmodium falciparum merozoites depends on the immune status of the host

Published 28th April, 2025

https://doi.org/10.1371/journal.ppat.1013107

Related Studies

2) Acquired immunity to malaria.

https://doi.org/10.1128/CMR.00025-08

3) Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against Plasmodium falciparum CyRPA.

https://doi.org/10.3389/fimmu.2021.716305

4) Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A.

https://doi.org/10.1038/s41598-020-63611-6

5) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

https://doi.org/10.1128/CVI.00042-09


Related Articles

An unhandled error has occurred. Reload 🗙